News
What changed, and when
FDA, DEA and WADA actions that change how peptides may be made, prescribed or used in sport. Each story is dated by when the action happened and links to the notice, letter or list it is based on.
October 2026
HHS
HHS interim policy covers 6 peptides for compounding
On Oct 28, 2026 HHS said it will not act against 503A compounding of BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500 under conditions. Not FDA approval.
September 2026
WADA
WADA 2027 List names peptides as S0 examples
WADA published its 2027 Prohibited List in September 2026, in force January 1, 2027. S0 now names peptides as examples. GLP-1 status is unchanged.
July 2026
FDA
FDA advisers review seven peptides for compounding
FDA's compounding advisers met July 23-24, 2026 on BPC-157, KPV, TB-500, MOTS-c, emideltide, Semax and Epitalon. FDA staff proposed against all seven.
May 2026
FDA
FDA proposes keeping GLP-1s off the 503B bulks list
A May 1, 2026 FDA notice proposes leaving semaglutide, tirzepatide and liraglutide off the 503B bulks list. Comments closed July 30, 2026.
April 2026
FDA
Most peptides leave FDA's Category 2 list
FDA's Category 2 list now names only kisspeptin-10 and ibutamoren from this site. BPC-157, TB-500 and others left after nominators withdrew.
March 2026
FDA
FDA warns 30 telehealth firms over compounded GLP-1 ads
On March 3, 2026, FDA announced 30 warning letters to telehealth firms over claims that compounded GLP-1s match approved drugs or hide who makes them.
December 2025
DEA
DEA telemedicine flexibilities run through 2026
DEA and HHS extended telemedicine prescribing of controlled medications through December 31, 2026. None of the peptides on this site is DEA controlled.